dc.contributor.author | Ergenç, İlkay | |
dc.contributor.author | Gözaydinoğlu, Büşra | |
dc.contributor.author | Keklikkıran, Çağlayan | |
dc.contributor.author | Yılmaz, Yusuf | |
dc.date.accessioned | 2024-07-25T12:42:46Z | |
dc.date.available | 2024-07-25T12:42:46Z | |
dc.date.issued | 2024 | en_US |
dc.identifier.citation | Ergenc, I., Gozaydinoglu, B., Keklikkiran, C., & Yilmaz, Y. (2024). Optimal testing strategies for incidental anti-mitochondrial M2 antibody-positive patients. Hepatology Forum, 5 (3), 165-166. http://doi.org/10.14744/hf.2024.2024.0007 | en_US |
dc.identifier.issn | 1307-5888 | |
dc.identifier.issn | 2757-7392 | |
dc.identifier.uri | http://doi.org/10.14744/hf.2024.2024.0007 | |
dc.identifier.uri | https://hdl.handle.net/11436/9203 | |
dc.description.abstract | We carefully considered the letter entitled “Optimal testing strategies
for incidental anti-mitochondrial M2 antibody-positive patients.” We
sincerely appreciate the authors’ insights and the thoughtful review
of our paper, “The risk of development of primary biliary cholangitis
among incidental antimitochondrial M2 antibody-positive patients”.[1,2]
We wish to offer clarification on the issues raised in the letter. | en_US |
dc.language.iso | eng | en_US |
dc.publisher | Kare Publishing | en_US |
dc.rights | info:eu-repo/semantics/openAccess | en_US |
dc.title | Optimal testing strategies for incidental anti-mitochondrial M2 antibody-positive patients | en_US |
dc.type | letter | en_US |
dc.contributor.department | RTEÜ, Tıp Fakültesi, Dahili Tıp Bilimleri Bölümü | en_US |
dc.contributor.institutionauthor | Keklikkıran, Çağlayan | |
dc.contributor.institutionauthor | Yılmaz, Yusuf | |
dc.identifier.doi | 10.14744/hf.2024.2024.0007 | en_US |
dc.identifier.volume | 5 | en_US |
dc.identifier.issue | 3 | en_US |
dc.identifier.startpage | 165 | en_US |
dc.identifier.endpage | 166 | en_US |
dc.relation.journal | Hepatology Forum | en_US |
dc.relation.publicationcategory | Diğer | en_US |